ATMI acquires Artelis
Expands portfolio of bioprocess manufacturing and single-use technology products
ATMI, a US supplier of single-use bioprocess systems and consumables to the life sciences industry, has bought Belgian biotechnology firm Artelis, which specialises in bioprocesses and technologies for cell culture research and manufacturing scale-up.
ATMI says the acquisition will add complementary biopharmaceutical process expertise to its existing ultra-pure single-use films, bioreactors, and mixing systems for characterising, developing, and manufacturing biopharmaceuticals.
ATMI was an early investor in Artelis and has been partnering the firm since 2006 on the development of disposable systems for cell culture.
‘Artelis represents a compelling strategic fit for us and expands ATMI’s commitment to the life sciences market,’ said Mario Philips, senior vice president and general manager of ATMI LifeSciences.
‘While they’re still at an early stage from a commercial ramp standpoint, their close collaboration with customers and world-class results in cell line development and cell culture technology allow us to provide the biopharmaceutical sector with the industry’s most comprehensive single-use solutions and technical support.’
Artelis’ leading product is the iCELLis 1000 disposable bioreactor for the production of proteins, viruses and cells.
